| Job Title: |
Postdoctoral fellow |
| Job Number: |
4014654 |
| Date Posted: |
07/15/2014 |
| Application Deadline: |
8/20/2014 |
|
|
|
Job Description
A high productive University of Florida lab is seeking US trained PhD postdoctoral fellows interested in translational research and drug development. Foreign trained candidate should not applied as their credentials are very difficult to validate. We have a large, well-equipped laboratory is located in the new Cancer Center at the University of Florida (Gainesville, Florida). Our laboratory studies how two anticancer genes, BRG1 and BRM are silenced in cancer. Our research encompasses the pursuit of drug development, exploring biomarkers for cancer risk and understand the mechanisms of epigenetic silencing. An ideal candidate should have 2-5 years of postdoctoral experience completed in the US. Postdoctoral fellows will be involved in high throughput drug screening and in the validation of compound hits. Postdoctoral fellows must be well versed in molecular biology techniques such as western blotting, PCR, Q-PCR, cell culture, purification of nucleic acid and using and production of lentil virus. In particular, experience in ChIP assay is highly recommended. Postdoctoral fellow must be willing to work with mice as well. For a review of our research, see Oncogene April 2009. Please list times and dates when you might available for a phone interview. After one to two phone interviews, top candidates will be asked to visit our laboratory in Florida for a formal interview. Salary range from $35-$45k depending on experience and ability. Please contact Dr. David Reisman M.D., Ph.D. at dnreisman@ufl.edu. Please forward CV and contact information for three references. Recent papers as listed below
1) Reisman D, Glaros S. and Thompson E.A. SWI/SNF and Cancer, 2009, Oncogene p1-16. 2009 Apr 9;28(14):1653-68.
2) Vanessa Gorden, Colin Rogers, David Reisman. Alterations in SWI/SNF in human cancers (2010) Oncology Reviews, 2010, Volume 4, Number 2, Pages 89-99
3) Liu G, Gramling S, Munoz D, Cheng D, Azad AK, Mirshams M, Chen Z, Xu W, Roberts H, Shepherd FA, Tsao MS, Reisman D. Two novel functional BRM insertion promoter polymorphisms, loss of BRM expression, and lung cancer risk. Oncogene. 2011 Jul 21;30(29):3295-304
4) Gramling S, Rogers C, Liu G, Reisman D. Pharmacologic reversal of epigenetic silencing of the anticancer protein, BRM, a novel targeted treatment strategy Oncogene. 2011 Jul 21;30(29):3289-94
1) 5) Bhaskar Kahali, Jinlong Yu, Stefanie B. Marquez, K. W. Thompson, Shermi Y. Liang1, Li Lu and David Reisman, The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors Oncotargets May 2014
2) 6) Kahali B, Marquez S, Thompson K, Gramling S, Liang S, Lu L, Aponick A, and David Reisman, Flavonoids from Each of the Six Structural Groups Reactivate BRM, A Possible Co-factor for the Anti-Cancer Gene Effects of Flavonoids: Accepted to Carcinogenesis 5/ 2014
| |
| |
| |
| Contact: |
David Reisman
Medicine
University of Florida
8830 SW 45th blvd
Gainesville, FL 32608
United States
Phone: 352 273 6000
Email: dnreisman ufl.edu | | | |
